HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for itself in the cardiac care field by building an intellectual-property portfolio focused on enabling 12-lead ECG diagnostics outside of a medical setting. Most recently, HeartBeam announced that it was issued a new patent, which enables generation of a synthesized 12-lead ESG by the HeartBeam AIMIGo(TM) credit card-sized device, by the United States Patent and Trademark Office (‘USPTO’)… The HeartBeam AIMI-platform technology is anticipated to assist health care professionals in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen,” a recent article reads. “We are proud that HeartBeam has been recognized for our unique approach to heart attack diagnosis,” HeartBeam CEO and Founder Branislav Vajdic, PhD., is quoted as saying. “Our goal is to provide a solution that offers both health care professionals and patients peace of mind regarding their diagnosis and treatment plan.”

To view the full article, visit https://ibn.fm/UmIMK

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork